Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal to manufacture...
Reexamination Certificate
2005-07-26
2005-07-26
Li, Q. Janice (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal to manufacture...
C800S005000, C800S006000, C800S013000, C800S018000
Reexamination Certificate
active
06921846
ABSTRACT:
The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized animal having antibody-producing cells with disrupted peripheral tolerance. The invention also provides a method for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized animal having antibody-producing cells with disrupted peripheral tolerance, for in vitro and in vivo clinical diagnostics and therapeutics.
REFERENCES:
patent: 5223410 (1993-06-01), Gargan et al.
patent: 5675063 (1997-10-01), Knight et al.
patent: WO 96/14401 (1995-11-01), None
Engel et al, Immunity 1995;3:39-50.
Nielsen et al, EMBO J 1983;2:115-9.
Mullins et al. Perspectives series: Molecular medcine in genetically engineered animals pp. 1557-1562 1996 vol. 97, No. 7.
Hammer et al. Genetic engineering of mammalian embryos pp. 269-278 Jul. 1986.
Wall et al. Transgenic dairy cattle: genetic engineering on a large scale pp. 2213-2224 1997.
A Strasser et al., Proc. Natl. Acad. Sci, USA, “Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease,” Oct. 1991, vol. 88, pp. 8661-8665.
GJ Hammerling et al., Proc. Natl. Sci USA, “Self-tolerance to HLA focuses the response of immunized HLA-transgenic mice on production of antibody to precise polymorphic HLA alloantigens,” Jan. 1990, vol. 87, pp. 235-239.
S Yoshino et al., European Journal of Pharmacology, “Effect of a monoclonal antibody against interleukin-4 on the induction of oral tolerance in mice,” Oct. 1997, 336: 203-209.
Bohlen et al., “Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies,” Cancer Research, p. 4310-4314, (Sep. 15, 1993).
Burnett et al., “Human Monoclonal Antibodies to Defined Antigens,” Human Hybridomas and Mab, Plenum Press, p. 113-133, (1985).
Brink et al., “Immunoglobulin M and D Antigen Receptors are Both Capable of Mediating B Lymphocyte Activation, Deletion, to Energy After Interaction with Specific Antigen,” J. Exp. Med., p. 991-1005, (Oct. 1992).
Sato et al., “CD19 Regulates B Lymphocyte Signaling Thresholds Critical for the Development of B-1 Lineage Cells and Autoimmunity,” J. Immunology, vol. 157, p. 4371-4378, (1996).
Zhou et al., “Tissue-Specific Expression of the Human CD19 Gene in Transgenic Mice Inhibits Antigen-Independent B-Lymphocyte Development,” Molecular and Cellular Biology, vol.14 (No. 6), p. 3884-3894, (Jun., 1994).
PCT International Search Report dated Mar. 2, 1999 for corresponding PCT application No. PCT/US98/25253.
Tedder et al., “The CD19-CD21 Complex Regulates Signal Review Transduction Thresholds Governing Humoral Immunity and Autoimmunity,” Immunity, vol. 6, p. 107-118, (Feb., 1997).
Duke University
Jenkins & Wilson & Taylor, P.A.
Li Q. Janice
LandOfFree
Antibody production methods relating to disruption of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody production methods relating to disruption of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody production methods relating to disruption of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3420701